Serum β-HCG and CA-125 as tumor markers in a patient with osteosarcoma: Case report

Tumori

Volumn 97, Issue 1, 2011, Pages 109-114

  Boss, David S ^a   Glen, Hilary ^b   Beijnen, Jos H ^c,d   De Jong, Daphne ^a   Wanders, Jantien ^e   Evans, T R Jeffry ^b   Schellens, Jan H M ^a,d  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^c SLOTERVAART HOSPITAL   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

^e EISAI CO LTD   (Japan)

Author keywords

Angiogenesis inhibitor; Case report; Osteosarcoma; Tumor marker

Indexed keywords

CA 125 ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; E 7080; ETOPOSIDE; IFOSFAMIDE; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CANCER SCREENING; CASE REPORT; CONTINUOUS INFUSION; DRUG WITHDRAWAL; FEMALE; FEMUR TUMOR; HORMONE BLOOD LEVEL; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MULTIPLE CYCLE TREATMENT; OSTEOSARCOMA; TREATMENT OUTCOME;

EID: 79953907907     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161109700119     Document Type: Article

References (24)

1. Keay SD, Vatish M, Karteris E, Hillhouse EW, Randeva HS: The role of hCG in reproductive medicine. BJOG, 111: 1218-1228, 2004. (Pubitemid 39472167)
2. Fiala C, Safar P, Bygdeman M, Gemzell-Danielsson K: Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. Eur J Obstet Gynecol Reprod Biol, 109: 190-195, 2003. (Pubitemid 36814085)
3. Demirtas E, Krishnamurthy S, Tulandi T: Elevated serum beta-human chorionic gonadotropin in nonpregnant conditions. Obstet Gynecol Surv, 62: 675-679, 2007. (Pubitemid 47493929)
4. Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K: New tumor markers: CA125 and beyond. Int J Gynecol Cancer,15 (Suppl 3): 274-281, 2005. (Pubitemid 43096594)
5. Hedman M, Arnberg H, Wernlund J, Riska H, Brodin O: Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma. Anticancer Res, 23: 531-536, 2003. (Pubitemid 36358446)
6. de Larrea CF, Cibeira MT, Vallansot R, Colomo L, Bladé J: Increased serum tumor markers (CA125 and CA15.3) in primary plasma cell leukemia: a case report and review of the literature. Clin Lymphoma Myeloma, 8: 312-314, 2008.
7. Dilek I, Ayakta H, Demir C, Meral C, Ozturk M: CA 125 levels in patients with non-Hodgkin lymphoma and other hematologic malignancies. Clin Lab Haematol, 27: 51-55, 2005. (Pubitemid 40293377)
8. Leonard GD, Low JA, Berman AW, Swain SM: CA 125 elevation in breast cancer: a case report and review of the literature. Breast J, 10: 146-149, 2004. (Pubitemid 38375037)
9. Goonewardene TI, Hall MR, Rustin GJ: Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol, 8: 813-821, 2007. (Pubitemid 47308670)
10. Sevinc A, Adli M, Kalender ME, Camci C: Benign causes of increased serum CA-125 concentration. Lancet Oncol, 8: 1054-1055, 2007. (Pubitemid 350182965)
11. Sevinc A, Camci C, Turk HM, Buyukberber S: How to inter pret serum CA 125 levels in patients with serosal involvement? A clinical dilemma. Oncology, 65: 1-6, 2003. (Pubitemid 36829084)
12. Chou AJ, Gorlick R: Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther, 6: 1075-1085, 2006. (Pubitemid 44203385)
13. Lamoureux F, Trichet V, Chipoy C, Blanchard F, Gouin F, Redini F: Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies. Expert Rev Anticancer Ther, 7: 169-181, 2007. (Pubitemid 46277282)
14. Sakamoto A, Iwamoto Y: Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy. Rev Recent Clin Trials, 3: 228-231, 2008.
15. Leidinger B, Bielack S, Koehler G, Vieth V, Winkelmann W, Gosheger G: High level of beta-hCG simulating pregnancy in recurrent osteosarcoma: case report and review of literature. J Cancer Res Clin Oncol, 130: 357-361, 2004. (Pubitemid 38858347)
16. Tholander B, Lindgren A, Taube A, Stenson S: Immunohistochemical detection of CA-125 and carcinoembryonic antigen in ovarian tumors in relation to corresponding preoperative serum levels. Int J Gynecol Cancer, 2: 263-270, 1992.
17. Holcomb K, Francis M, Ruiz J, Abulafia O, Matthews RP, Lee YC: Pleomorphic rhabdomyosarcoma of the uterus in a postmenopausal woman with elevated serum CA125. Gynecol Oncol, 74: 499-501, 1999. (Pubitemid 29439899)
18. Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, Uenaka T, Asada M: E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer, 122: 664-671, 2008. (Pubitemid 350308963)
19. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M: Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res, 14: 5459-5465, 2008.
20. Ek ET, Ojaimi J, Kitagawa Y, Choong PF: Does the degree of intratumoural microvessel density and VEGF expression have prognostic significance in osteosarcoma? Oncol Rep, 16: 17-23, 2006.
21. Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M, Higashino F, Mezawa F, Okada F, Ishii S: Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res, 6: 572-577, 2000. (Pubitemid 30111481)
22. Lee YH, Tokunaga T, Oshika Y, Suto R, Yanagisawa K, Tomisawa M, Fukuda H, Nakano H, Abe S, Tateishi A, Kijima H, Yamazaki H, Tamaoki N, Ueyama Y, Nakamura M: Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer, 35: 1089-1093, 1999. (Pubitemid 29339192)
23. Ek ET, Ojaimi J, Kitagawa Y, Choong PF: Outcome of patients with osteosarcoma over 40 years of age: is angiogenesis a marker of survival? Int Semin Surg Oncol, 3: 7, 2006.
24. Reisinger K, Baal N, McKinnon T, Munstedt K, Zygmunt M: The gonadotropins: tissue-specific angiogenic factors? Mol Cell Endocrinol, 269: 65-80, 2007.